Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight

Foundayo (orforglipron) has a serious advantage over Novo Nordisk's Wegovy pill. Retatrutide, a subcutaneous triple hormone receptor agonist in phase 3 trials, could be a game changer.